Skip to main content

Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models.

Publication ,  Journal Article
Nief, CA; Swartz, AM; Chelales, E; Sheu, LY; Crouch, BT; Ramanujam, N; Nair, SK
Published in: Cancers (Basel)
September 25, 2022

Ethanol ablation is a minimally invasive, cost-effective method of destroying tumor tissue through an intratumoral injection of high concentrations of cytotoxic alcohol. Ethyl-cellulose ethanol (ECE) ablation, a modified version of ethanol ablation, contains the phase-changing polysaccharide ethyl-cellulose to reduce ethanol leakage away from the tumor. Ablation produces tissue necrosis and initiates a wound healing process; however, the characteristic of the immunologic events after ECE ablation of tumors has yet to be explored. Models of triple-negative breast cancer (TNBC), which are classically immunosuppressive and difficult to treat clinically, were used to characterize the immunophenotypic changes after ECE ablation. In poorly invasive TNBC rodent models, the injury to the tumor induced by ECE increased tumor infiltrating lymphocytes (TILs) and reduced tumor growth. In a metastatic TNBC model (4T1), TILs did not increase after ECE ablation, though lung metastases were reduced. 4T1 tumors secrete high levels of granulocytic colony stimulating factor (G-CSF), which induces a suppressive milieu of granulocytic myeloid-derived suppressor cells (gMDSCs) aiding in the formation of metastases and suppression of antitumor immunity. We found that a single intratumoral injection of ECE normalized tumor-induced myeloid changes: reducing serum G-CSF and gMDSC populations. ECE also dampened the suppressive strength of gMDSC on CD4 and CD8 cell proliferation, which are crucial for anti-tumor immunity. To demonstrate the utility of these findings, ECE ablation was administered before checkpoint inhibitor (CPI) therapy in the 4T1 model and was found to significantly increase survival compared to a control of saline and CPI. Sixty days after tumor implant no primary tumors or metastatic lung lesions were found in 6/10 mice treated with CPI plus ECE, compared to 1/10 with ECE alone and 0/10 with CPI and saline.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

September 25, 2022

Volume

14

Issue

19

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nief, C. A., Swartz, A. M., Chelales, E., Sheu, L. Y., Crouch, B. T., Ramanujam, N., & Nair, S. K. (2022). Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. Cancers (Basel), 14(19). https://doi.org/10.3390/cancers14194669
Nief, Corrine A., Adam M. Swartz, Erika Chelales, Lauren Y. Sheu, Brian T. Crouch, Nirmala Ramanujam, and Smita K. Nair. “Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models.Cancers (Basel) 14, no. 19 (September 25, 2022). https://doi.org/10.3390/cancers14194669.
Nief CA, Swartz AM, Chelales E, Sheu LY, Crouch BT, Ramanujam N, et al. Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. Cancers (Basel). 2022 Sep 25;14(19).
Nief, Corrine A., et al. “Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models.Cancers (Basel), vol. 14, no. 19, Sept. 2022. Pubmed, doi:10.3390/cancers14194669.
Nief CA, Swartz AM, Chelales E, Sheu LY, Crouch BT, Ramanujam N, Nair SK. Ethanol Ablation Therapy Drives Immune-Mediated Antitumor Effects in Murine Breast Cancer Models. Cancers (Basel). 2022 Sep 25;14(19).

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

September 25, 2022

Volume

14

Issue

19

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis